An adequate medication trial requires a suitable medicine, appropriate dose or exposure, sufficient duration and a meaningful assessment of response. The details depend on the drug and clinical situation. Time spent at a very low introductory dose may not represent a full trial, while intolerable effects can prevent an otherwise appropriate regimen from being tested adequately.
Treatment resistance describes persistent clinically significant symptoms despite appropriately delivered treatment. In schizophrenia, the term usually concerns inadequate response to adequate antipsychotic trials, but definitions require attention to exposure, duration and outcomes. It should not be applied simply because recovery is incomplete or because one medicine was stopped early due to adverse effects.
Clinicians review records, the person’s experience and evidence of consistent treatment. Interactions, absorption and metabolism can affect exposure. Drug-level testing is useful in selected circumstances but does not answer every question. Outcomes should be compared with baseline symptoms and functioning. Simply increasing a dose indefinitely does not make a trial better. A structured review helps distinguish lack of efficacy from inadequate delivery or poor tolerability and provides a sounder basis for deciding what treatment should follow.
A trial’s interpretation depends on the period of effective exposure, not simply the time since the first prescription. Dose changes, interruptions and interactions can alter that period. Documentation should also record adverse effects and the reason for stopping. This makes the treatment history useful for future decisions and avoids counting incomplete or intolerable trials as identical evidence of pharmacological non-response.
Further reading: Open-access research; Research record 3046553.
Comments are closed, but trackbacks and pingbacks are open.